Heart-Type Fatty Acid Binding Protein Is Associated with Proteinuria in Obesity

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Chen, Hui Mei ^a   Zheng, Chun Xia ^a   Gao, Qing ^a   Ge, Yong Chun ^a   Liu, Zhi Hong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; SYNAPTOPODIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; FOCAL GLOMERULOSCLEROSIS; GLOMERULOPATHY; GLOMERULUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; KIDNEY TUBULE; MALE; MOUSE; NONHUMAN; OBESITY; OBESITY RELATED GLOMERULOPATHY; PODOCYTE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEINURIA; UPREGULATION; WAIST CIRCUMFERENCE;

ANIMALS; FATTY ACID-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; OBESITY; PODOCYTES; PROTEINURIA;

MUS;

EID: 84866522336     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045691     Document Type: Article

References (28)

1. Yanovski SZ, Yanovski JA, (2011) Obesity prevalence in the United States-up, down, or sideways? N Engl J Med 364: 987-989.
2. Raz I, Del Prato S, (2011) Introduction to the Third World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy): outcome studies versus clinical experience in the treatment of diabetes. Diabetes Care 34Suppl 2: S99-100.
3. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD, (2001) Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 59: 1498-1509.
4. Tran HA, (2004) Obesity-related glomerulopathy. J Clin Endocrinol Metab 89: 6358.
5. Chen HM, Li SJ, Chen HP, Wang QW, Li LS, et al. (2008) Obesity-related glomerulopathy in China: a case series of 90 patients. Am J Kidney Dis 52: 58-65.
6. Sheridan AM, Fitzpatrick S, Wang C, Wheeler DC, Lieberthal W, (1996) Lipid peroxidation contributes to hydrogen peroxide induced cytotoxicity in renal epithelial cells. Kidney Int 49: 88-93.
7. Hertzel AV, Bernlohr DA, (2000) The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol Metab 11: 175-180.
8. Wu Y, Liu Z, Xiang Z, Zeng C, Chen Z, et al. (2006) Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology 147: 44-50.
9. Zimmerman AW, Veerkamp JH, (2002) New insights into the structure and function of fatty acid-binding proteins. Cell Mol Life Sci 59: 1096-1116.
10. Kimura H, Fujii H, Suzuki S, Ono T, Arakawa M, et al. (1999) Lipid-binding proteins in rat and human kidney. Kidney Int Suppl 71: S159-162.
11. Chen HM, Liu ZH, Zeng CH, Li SJ, Wang QW, et al. (2006) Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis 48: 772-779.
12. Stieger N, Worthmann K, Schiffer M, (2011) The role of metabolic and haemodynamic factors in podocyte injury in diabetes. Diabetes Metab Res Rev 27: 207-215.
13. Qu HQ, Li Q, Rentfro AR, Fisher-Hoch SP, McCormick JB, (2011) The definition of insulin resistance using HOMA-IR for Americans of Mexican descent using machine learning. PLoS One 6: e21041.
14. Tanimoto M, Fan Q, Gohda T, Shike T, Makita Y, et al. (2004) Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. Metabolism 53: 1473-1479.
15. Kume S, Uzu T, Araki S, Sugimoto T, Isshiki K, et al. (2007) Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. J Am Soc Nephrol 18: 2715-2723.
16. Sharma K, (2009) The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int 76: 145-148.
17. Wang Z, Jiang T, Li J, Proctor G, McManaman JL, et al. (2005) Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 54: 2328-2335.
18. Negishi K, Noiri E, Sugaya T, Li S, Megyesi J, et al. (2007) A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure. Kidney Int 72: 348-358.
19. Matsui K, Kamijo-Ikemorif A, Sugaya T, Yasuda T, Kimura K, (2011) Renal liver-type fatty acid binding protein (L-FABP) attenuates acute kidney injury in aristolochic acid nephrotoxicity. Am J Pathol 178: 1021-1032.
20. Zuo N, Suzuki Y, Sugaya T, Osaki K, Kanaguchi Y, et al. (2011) Protective effects of tubular liver-type fatty acid-binding protein against glomerular damage in murine IgA nephropathy. Nephrol Dial Transplant 26: 2127-2137.
21. Praga M, Hernandez E, Morales E, Campos AP, Valero MA, et al. (2001) Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 16: 1790-1798.
22. Praga M, (2002) Obesity-a neglected culprit in renal disease. Nephrol Dial Transplant 17: 1157-1159.
23. Blanco S, Vaquero M, Gomez-Guerrero C, Lopez D, Egido J, et al. (2005) Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension. Am J Hypertens 18: 557-565.
24. Kramer H, Reboussin D, Bertoni AG, Marcovina S, Lipkin E, et al. (2009) Obesity and albuminuria among adults with type 2 diabetes: the Look AHEAD (Action for Health in Diabetes) Study. Diabetes Care 32: 851-853.
25. Gao Q, Shen W, Qin W, Zheng C, Zhang M, et al. (2010) Treatment of db/db diabetic mice with triptolide: a novel therapy for diabetic nephropathy. Nephrol Dial Transplant 25: 3539-3547.
26. Pollak MR, (2002) Inherited podocytopathies: FSGS and nephrotic syndrome from a genetic viewpoint. J Am Soc Nephrol 13: 3016-3023.
27. Mayrhofer C, Krieger S, Huttary N, Chang MW, Grillari J, et al. (2009) Alterations in fatty acid utilization and an impaired antioxidant defense mechanism are early events in podocyte injury: a proteomic analysis. Am J Pathol 174: 1191-1202.
28. Chen HM, Chen Y, Zhang YD, Zhang PP, Chen HP, et al. (2011) Evaluation of metabolic risk marker in obesity-related glomerulopathy. J Ren Nutr 21: 309-315.